African sleeping sickness
AUTOR(ES)
Checchi, Francesco
FONTE
BMJ Publishing Group Ltd.
RESUMO
Eflornithine should be the drug of choice for stage 2 disease, but resistance must be monitored
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2276269Documentos Relacionados
- Glycosylphosphatidylinositol biosynthesis validated as a drug target for African sleeping sickness
- Galactose metabolism is essential for the African sleeping sickness parasite Trypanosoma brucei
- Trypanosoma brucei CTP synthetase: A target for the treatment of African sleeping sickness
- Chemical validation of GPI biosynthesis as a drug target against African sleeping sickness
- History of Sleeping Sickness in East Africa